Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment. (NCT01975142)
Patients with metastatic breast cancer considered HER2 negative are included are screened for HER2-amplified circulating tumor cells. If at least HER2-amplified circulating tumor cell is detected, patients are treated by ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech, Inc.) in a single ar phase II with an adaptive design.
This trial is sponsored by Institut Curie. 
- Condition: Metastatic Breast Cancer: HER2 Negative on Primary Tumor
- Phase: II
- Estimated Enrollment: 480
- Start: October 2013
- Estimated Primary Completion: November 2016
- Last verified: October 2014
Last Editorial review: July 30, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.